Clinical Trial Update: Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating efficacy and safety of triple therapy in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Interstitial Lung Disease

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Dermatomyositis, Adult Type, Interstitial Lung Disease | Phase 4 | Status: UNKNOWN